for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gracell Biotechnologies Inc (ADR)

GRCL.O

Latest Trade

14.85USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.75

 - 

33.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.85
Open
--
Volume
--
3M AVG Volume
2.61
Today's High
--
Today's Low
--
52 Week High
33.70
52 Week Low
9.75
Shares Out (MIL)
336.07
Market Cap (MIL)
998.12
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Gracell Biotechnologies Reports Qtrly Loss Per Share $0.05

Gracell Biotechnologies - Entered Into Manufacturing Service Agreement With Lonza

Gracell Biotechnologies Reports Fourth Quarter And Fiscal Year 2020 Unaudited Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gracell Biotechnologies Inc (ADR)

Gracell Biotechnologies Inc is a China-based clinical-stage biopharmaceutical company focused on discovering and developing cell therapies for the treatment of cancers. The Company is primarily focused on disrupting conventional approaches to chimeric antigen receptor (CAR) thymus (T) cell therapies by leveraging its technology platforms FasTCAR and TruUCAR. With FasTCAR, the Company is able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing. With TruUCAR, the Company is able derive T cells from non-human leukocyte antigen (HLA)-matched healthy donors to generate allogeneic CAR-T cell therapies. The Company is levering its technology platform to develop various drug candidates, including GC012F, GC019F, GC007F, GC027 and GC007g.

Industry

Business Services

Contact Info

Building 3

418 Guilin Road, Xuhui District

SHANGHAI, SHA

200030

China

+86.21.64031522

http://www.gracellbio.com/

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-1.100
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.55
LT Debt To Equity (MRQ)
6.34
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up